Navigation Links
Stent Studies Tied to Rapid Changes in Use
Date:7/28/2009

Fast dissemination of data may become main stimulus for change, experts say

TUESDAY, July 28 (HealthDay News) -- Rapid dissemination of new data about the risks posed by drug-eluting stents led to an almost immediate decrease in the use of the stents, according to a new report.

Drug-eluting stents are coated with drugs meant to prevent re-narrowing of coronary arteries.

An analysis of patient registries showed that between January and September 2006, about 90 percent of people who had a type of heart attack called a non-ST-elevation myocardial infarction and underwent coronary stent implantation received drug-eluting stents.

That September, a number of studies presented at a European Society of Cardiology meeting said that the risk of blood clots was higher among people who received drug-eluting stents than among those who received bare-metal stents.

By the end of March 2007, the use of drug-eluting stents had declined to 67 percent and continued to drop to 58 percent by the start of 2008, the researchers found. Their study is published online in Circulation: Cardiovascular Quality and Outcomes.

"There was a rapid change of practice patterns after these presentations in September 2006," the study's lead author, Dr. Matthew T. Roe, an associate professor of medicine at Duke University Medical Center and the Duke Clinical Research Institute in Durham, N.C., said in an American Heart Association news release. "To our knowledge, this was the most rapid change in practice patterns in cardiology. We presume it was because of rapid uptake of information."

The findings suggest that fast distribution of new information through media and scientific outlets could become the "predominant stimulus for change in practice in the future," Roe and his colleagues said.

Dr. Clyde W. Yancy, president of the American Heart Association, said in the news release that the study "demonstrates the dynamic shifts that are occurring in the distribution of medical information."

"The opportunity to widely share important findings that promptly impact practice is becoming a powerful tool to drive change," Yancy said. "The requirements for prompt but thorough peer review and nimble responsiveness to new data are evident. Managing this new health IT space will require focus, assessment and realignment."

More information

The Society for Vascular Surgery has more about angioplasty and stenting.



-- Robert Preidt



SOURCE: American Heart Association, news release, July 28, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. QHR Client Hospitals Lauded for Consistently High Quality Standards, Exceeding Patient Expectations
2. FDA Approves Boston Scientifics TAXUS(R) Liberte(R) Long Stent
3. AbbeyMoor Medical Receives FDA Approval for Design Improvements to The Spanner(TM) Prostatic Stent
4. CorNova(R) Receives CE Mark Approval for Valecor Platinum(R) Coronary Stent System
5. Abbott Receives CE Mark for Companys Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Advancing Leadership Position
6. Newest Coated Stent Does Well in Real-World Trial
7. AMA Supports Health System Reform Alternatives Consistent With Principles of Pluralism, Freedom of Choice, Freedom of Practice and Universal Access for Patients
8. Analysis of drug-eluting stents data demonstrates safety, efficacy in on-and-off-label use
9. InstaMed Achieves CAQH CORE Rules Certification, Streamlines Provider Access to Consistent Electronic Eligibility, Benefits and Patient Financial Liability Data
10. Abbott Initiates Trial of Next-Generation XIENCE PRIME(TM) Drug Eluting Stent, Building Upon Superior Outcomes from SPIRIT Family of Trials
11. Broncus Technologies Exhale Stent and Other New Devices to Prompt Robust Growth In Emphysema Treatment Market, According to Millennium Research Group
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stent Studies Tied to Rapid Changes in Use
(Date:12/2/2016)... ... ... over twenty-four years, Doctors on Liens has published a directory of the top ... care. When the company started in 1997, the directory was a single page focusing ... now ten-page directory features a vast array of medical specialists stretching from Sacramento ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to ... Annual Election Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to ... drug plan (Part D) need to make changes during this period order for their ...
(Date:12/2/2016)... NY (PRWEB) , ... December 02, 2016 , ... More ... school and while 84 percent of parents report speaking with their child about sex ... and sexually transmitted diseases. , Mediaplanet is proud to announce the launch of its ...
(Date:12/2/2016)... ... December 02, 2016 , ... Sourced from the Isbre ... unique properties including its unmatched natural purity of just 6 ppm TDS (Total Dissolved ... , Nothing Water has been available in several ShopRite and FoodTown stores in NJ ...
(Date:12/2/2016)... ... December 02, 2016 , ... On ... individuals and families from eight different sites throughout Miami-Dade and Broward counties. This ... volunteers worked very hard on Thanksgiving morning by putting together individual meals via ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... , Dec. 1, 2016  Today, Simpson Healthcare ... the honor of being selected as winners of multiple ... Healthcare Executives Website at the PLATINUM level, Blue Zones ... Module at the GOLD Level, and our proprietary 3ConneX ... At Simpson Healthcare Executives, we are excited to showcase ...
(Date:12/2/2016)... Dec. 2, 2016  UCB is pleased to announce that 12 ... upcoming 70 th American Epilepsy Society (AES) Annual Meeting, ... TX , USA. 1-12 Data ... profile of VIMPAT ® (lacosamide) CV and BRIVIACT ® ... on the current state of the union of epilepsy care ...
(Date:12/2/2016)... 2, 2016 Allergan plc (NYSE: AGN ... on its previously announced Accelerated Share Repurchase (ASR) Program. ... ... As previously announced, the Company entered into a variable ... Company will repurchase $10 billion of its ordinary shares. Approximately ...
Breaking Medicine Technology: